Lyme Disease in Urban Areas, Chicago
To the Editor: Lyme disease is a multisystem illness caused by infection with the tickborne spirochete Borrelia burgdorferi. Most infections in the United States occur in the Northeast and upper Midwest, and the midwestern focus now includes Illinois (1, 2) . Previously, the greatest risk of contracting Lyme disease in the Midwest was confi ned to the northernmost states (Wisconsin and Minnesota) and did not encroach into heavily populated areas around the city of Chicago. However, we showed recently that B. burgdorferi-infected Ixodes scapularis ticks were recovered from sites in Cook and DuPage counties (3), but the percentages of infected ticks were low (<5%). Since that time, however, reports of Lyme disease in Cook County have been reviewed and individual I. scapularis tick submissions from Lake County, north of Chicago, have been received. We therefore surveyed new areas north of Chicago (closest was <1 mile from the city limits; farthest was ≈25 miles from the city limits) and examined additional ticks for infection with B. burgdorferi.
From December 2006 to May 2007, we collected 172 adult I. scapularis ticks from sites to the north and northwest of Chicago (Figure) . Adult ticks were collected because nymphal ticks are more diffi cult to obtain, and the infection rate in adult ticks is similar (1) . The tick midguts were removed aseptically, inoculated into tubes containing 1 mL of modifi ed Barbour-Stoenner-Kelly medium (4), incubated at 35ºC, and examined for spirochetes for up to 3 weeks. Spirochetes were recovered from 21 (32%) of 65 ticks and 40 (37%) of 107 ticks collected from sites in Cook and Lake counties, respectively. In addition, PCR using primers specifi c for outer surface protein A (5) confi rmed that the spirochetes were B. burgdorferi.
The fi ndings demonstrate that the midwestern endemic focus of (6,7). The high percentage of infected adult ticks identifi ed in this survey highlights the need for physicians in the Chicago area to become familiar with this recommendation, especially considering the high likelihood that nymphal I. scapularis ticks are similarly infected (1). Moreover, confi rmation of the increasing risk of contracting Lyme disease near metropolitan Chicago should provide impetus for more comprehensive studies to completely defi ne the risk of this potentially serious illness.
Oral Versus IV Treatment for Catheter-related Bloodstream Infections
To the Editor: I read with interest the article by Halton and Graves on the economics of catheter-related blood stream infections (1). The most important determinants of infection in a temporary central venous catheter (CVC) are location and duration (2) . Also important are aseptic CVC insertion and maintenance. Reducing the economic effects of CVCs is important, but I believe clinicians should use oral antimicrobial agents more often in place of intravenous (IV) antimicrobial therapy.
The economic and clinical benefi ts of using oral versus intravenous antimicrobial therapy are considerable. Oral therapy has important advantages over intravenous therapy administered via CVCs. Clinical advantages of oral antimicrobial therapy include the elimination of phlebitis CVC line infections. At equivalent doses, acquisition costs of oral agents are less than intravenous counterparts. Healthcare institutions charge IV administration fees per antimicrobial intravenous dose. Administrative cost for intravenous antimicrobial agents is US $10/dose. Intravenous antimicrobial administration costs are eliminated when drugs are administered orally. In hospitalized patients, oral antimicrobial therapy results in a decreased hospital length of stay with its attendant economic implications.
Oral therapy for serious systemic infections should be with high bioavailability drugs, i.e., >90%, which results in essentially the same serum/ tissue levels as if when administered by IV. Because all parenteral antimicrobial agents do not have an oral formulation, clinicians should select an equivalent oral agent with the same spectrum as its parenteral counterpart
